It promotes tumor angiogenesis and bladder cancer progression by targeting PTEN, which induces activation of the PI3K/AKT signaling pathway and suppresses maspin expression, ultimately leading to the upregulation of VEGF-C (57, 58). Here, AKT1 is linked to urinary bladder carcinoma.